#pleomorphic sarcoma definition
Explore tagged Tumblr posts
treatmentdisease-blog · 7 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2Es77Kl
Epithelioid sarcoma - foot and ankle bonetumor.org pleomorphic sarcoma definition
0 notes
imagecase · 4 years ago
Link
Introduction: Mediastinal masses represent a difficult challenge in terms of their diagnosis and treatment. We present a case of a patient clinically mimicking as achalasia. Case report: A 61-year-old man, with symptoms interpreted as achalasia, presented a huge mediastinal mass suspicious for sarcoma. Only definitive pathological examination after radical surgical resection evidenced a high-grade pleomorphic sarcoma of uncertain origin. Discussion: Mediastinum is a rare primary site of sarcoma, clinical diagnosis and pathological classification remain challenging. Surgery is still the only treatment affecting survival, even if it is not always possible. In our experience, surgical radical removal was possible after a multicompartmental approach and the patient is alive with no evidence of disease after nine months from surgery. Conclusion: Diagnosis of mediastinal sarcoma is still very difficult because of lack of pathognomonic symptoms and diagnostic work-up, clinical and pathological heterogeneity. Surgical aggressive approach is the only therapeutic option to extend survival.
Keywords: Mediastinal sarcoma; Huge mass; Rare tumor
0 notes
cancersfakianakis1 · 7 years ago
Text
Retrospective audit of 957 consecutive 18 F-FDG PET–CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma
Abstract
Background
The use of 18F-FDG PET–CT (PET–CT) is widespread in many cancer types compared to sarcoma. We report a large retrospective audit of PET–CT in bone and soft tissue sarcoma with varied grade in a single multi-disciplinary centre. We also sought to answer three questions. Firstly, the correlation between sarcoma sub-type and grade with 18FDG SUVmax, secondly, the practical uses of PET–CT in the clinical setting of staging (during initial diagnosis), restaging (new baseline prior to definitive intervention) and treatment response. Finally, we also attempted to evaluate the potential additional benefit of PET–CT over concurrent conventional CT and MRI.
Methods
A total of 957 consecutive PET–CT scans were performed in a single supra-regional centre in 493 sarcoma patients (excluding GIST) between 2007 and 2014. We compared, PET–CT SUVmax values in relation to histology and FNCCC grading. We compared PET–CT findings relative to concurrent conventional imaging (MRI and CT) in staging, restaging and treatment responses.
Results
High-grade (II/III) bone and soft tissue sarcoma correlated with high SUVmax, especially undifferentiated pleomorphic sarcoma, leiomyosarcoma, translocation induced sarcomas (Ewing, synovial, alveolar rhabdomyosarcoma), de-differentiated liposarcoma and osteosarcoma. Lower SUVmax values were observed in sarcomas of low histological grade (grade I), and in rare subtypes of intermediate grade soft tissue sarcoma (e.g. alveolar soft part sarcoma and solitary fibrous tumour). SUVmax variation was noted in malignant peripheral nerve sheath tumours, compared to the histologically benign plexiform neurofibroma, whereas PET–CT could clearly differentiate low from high-grade chondrosarcoma. We identified added utility of PET–CT in addition to MRI and CT in high-grade sarcoma of bone and soft tissues. An estimated 21% overall potential benefit was observed for PET–CT over CT/MRI, and in particular, in ‘upstaging’ of high-grade disease (from M0 to M1) where an additional 12% of cases were deemed M1 following PET–CT.
Conclusions
PET–CT in high-grade bone and soft tissue sarcoma can add significant benefit to routine CT/MRI staging. Further prospective and multi-centre evaluation of PET–CT is warranted to determine the actual predictive value and cost-effectiveness of PET–CT in directing clinical management of clinically complex and heterogeneous high-grade sarcomas.
https://ift.tt/2EwuMZM
0 notes
itsmedicinesfakianakis · 8 years ago
Text
Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma
Opinion Statement
Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) tumors share many clinical, etiologic, and histologic features and likely represent components of a tumor spectrum. In dermatologic oncology, differentiating between AFX and PDS is pivotal as tumors with histological features consistent with PDS are more likely to behave in a clinically aggressive manner. Importantly, the term “pleomorphic dermal sarcoma” (PDS) is a more appropriate designation than “undifferentiated pleomorphic sarcoma” (UPS) for describing deeper, more aggressive, histologically high-grade cutaneous tumors that otherwise resemble AFX. Surgery remains the gold standard for treatment. In the setting of AFX, excision with the Mohs micrographic technique appears to offer superior tumor control rates while maintaining greater tissue preservation over wide local excision and should be considered first line. In the setting of PDS, optimal management is less clear given the paucity of available data. However, due to its greater propensity to recur and metastasize, extirpation with complete tumor margin control appears paramount. The roles of imaging and SLNB in management and clinical outcomes of AFX and PDS are unclear given the lack of available data. In reality, these tools are unlikely to be helpful in most cases of AFX. However, in the setting of PDS, emerging literature indicates that these tumors are inherently higher risk, and thus, imaging and SLNB may be helpful in select cases. Additionally, radiation therapy may be of adjuvant benefit for these tumors when clear surgical margins cannot be obtained. While traditional chemotherapy has been largely ineffectual, the recent discovery of key oncogenetic mutations has allowed for the identification of several potential molecular drug targets that may have a therapeutic role with future study. In the unfortunate setting of metastatic disease, a multidisciplinary approach is optimal. Further studies are needed to establish definitive conclusions regarding risk stratification and best management practices.
from Therapeutics via xlomafota13 on Inoreader http://ift.tt/2f0MI7H
from OtoRhinoLaryngology - Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vXOsmi
0 notes
treatmentdisease-blog · 7 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2EfLyfO
Surgery for bone sarcoma in adults nyu langone medical center pleomorphic sarcoma definition
0 notes
treatmentdisease-blog · 7 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2pYZjNL
Adult ewing sarcoma survival and local control outcomes in 102 patients with localized disease pleomorphic sarcoma definition
0 notes
treatmentdisease-blog · 8 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2DaE8Ll
Mastocytoma - my best friend has cancer pleomorphic sarcoma definition
0 notes
treatmentdisease-blog · 8 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2yZaCZN
Brigham and women’s hospital tumor staging for cutaneous squamous cell carcinoma outperforms ajcc and uicc staging - the asco post ewing sarcoma translocation
0 notes
treatmentdisease-blog · 8 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2gmVzOC
Adult soft tissue sarcoma metastatic sarcoma lung
0 notes
treatmentdisease-blog · 8 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2x7z6Pj
Histiocytic sarcoma localised in the thyroid—a case report springerlink sarcoma clinic
0 notes
treatmentdisease-blog · 8 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2xmhxuG
Bone chondrosarcoma pleomorphic sarcoma lung
0 notes
treatmentdisease-blog · 8 years ago
Text
New Post has been published on Details of the treatment of certain diseases. Human Diseases and methods of treatment
New Post has been published on http://bit.ly/2xinito
Search results - seer inquiry system sarcoma treatment options
0 notes
cancersfakianakis1 · 8 years ago
Text
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Related Articles
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Cancer Biol Ther. 2017 Nov 03;:1-11
Authors: May CD, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Sannaa GAA, Bhalla AD, Wang WL, Lazar AJ, Torres KE
Abstract Undifferentiated pleomorphic sarcomas (UPSs) are aggressive mesenchymal malignancies with no definitive cell of origin or specific recurrent genetic hallmarks. These tumors are largely chemoresistant; thus, identification of potential therapeutic targets is necessary to improve patient outcome. Previous studies demonstrated that high expression of activated protein kinase B (AKT) in patients with UPS corresponds to poor disease-specific survival. Here, we demonstrate that inhibiting phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling using a small molecule inhibitor reduced UPS cell proliferation and motility and xenograft growth; however, increased phosphorylation of insulin-like growth factor 1 receptor (IGF1R) indicated the potential for adaptive resistance following treatment through compensatory receptor activation. Co-treatment with a dual PI3K/mTOR inhibitor and an anti-IGF1R kinase inhibitor reduced in vivo tumor growth rates despite a lack of antiproliferative effects in vitro. Moreover, this combination treatment significantly decreased UPS cell migration and invasion, which is linked to changes in p27 subcellular localization. Our results demonstrate that targeted inhibition of multiple components of the IGF1R/PI3K/mTOR pathway was more efficacious than single-agent therapy and suggest that co-targeting this pathway could be a beneficial therapeutic strategy for patients with UPS.
PMID: 29099264 [PubMed - as supplied by publisher]
http://ift.tt/2zhtS4a
0 notes
cancersfakianakis1 · 8 years ago
Text
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Related Articles
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Cancer Biol Ther. 2017 Nov 03;:1-11
Authors: May CD, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Sannaa GAA, Bhalla AD, Wang WL, Lazar AJ, Torres KE
Abstract Undifferentiated pleomorphic sarcomas (UPSs) are aggressive mesenchymal malignancies with no definitive cell of origin or specific recurrent genetic hallmarks. These tumors are largely chemoresistant; thus, identification of potential therapeutic targets is necessary to improve patient outcome. Previous studies demonstrated that high expression of activated protein kinase B (AKT) in patients with UPS corresponds to poor disease-specific survival. Here, we demonstrate that inhibiting phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling using a small molecule inhibitor reduced UPS cell proliferation and motility and xenograft growth; however, increased phosphorylation of insulin-like growth factor 1 receptor (IGF1R) indicated the potential for adaptive resistance following treatment through compensatory receptor activation. Co-treatment with a dual PI3K/mTOR inhibitor and an anti-IGF1R kinase inhibitor reduced in vivo tumor growth rates despite a lack of antiproliferative effects in vitro. Moreover, this combination treatment significantly decreased UPS cell migration and invasion, which is linked to changes in p27 subcellular localization. Our results demonstrate that targeted inhibition of multiple components of the IGF1R/PI3K/mTOR pathway was more efficacious than single-agent therapy and suggest that co-targeting this pathway could be a beneficial therapeutic strategy for patients with UPS.
PMID: 29099264 [PubMed - as supplied by publisher]
http://ift.tt/2zhtS4a
0 notes
cancersfakianakis1 · 8 years ago
Text
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Related Articles
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
Cancer Biol Ther. 2017 Nov 03;:1-11
Authors: May CD, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Sannaa GAA, Bhalla AD, Wang WL, Lazar AJ, Torres KE
Abstract Undifferentiated pleomorphic sarcomas (UPSs) are aggressive mesenchymal malignancies with no definitive cell of origin or specific recurrent genetic hallmarks. These tumors are largely chemoresistant; thus, identification of potential therapeutic targets is necessary to improve patient outcome. Previous studies demonstrated that high expression of activated protein kinase B (AKT) in patients with UPS corresponds to poor disease-specific survival. Here, we demonstrate that inhibiting phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling using a small molecule inhibitor reduced UPS cell proliferation and motility and xenograft growth; however, increased phosphorylation of insulin-like growth factor 1 receptor (IGF1R) indicated the potential for adaptive resistance following treatment through compensatory receptor activation. Co-treatment with a dual PI3K/mTOR inhibitor and an anti-IGF1R kinase inhibitor reduced in vivo tumor growth rates despite a lack of antiproliferative effects in vitro. Moreover, this combination treatment significantly decreased UPS cell migration and invasion, which is linked to changes in p27 subcellular localization. Our results demonstrate that targeted inhibition of multiple components of the IGF1R/PI3K/mTOR pathway was more efficacious than single-agent therapy and suggest that co-targeting this pathway could be a beneficial therapeutic strategy for patients with UPS.
PMID: 29099264 [PubMed - as supplied by publisher]
http://ift.tt/2zhtS4a
0 notes
cancersfakianakis1 · 8 years ago
Text
Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma
Opinion Statement
Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) tumors share many clinical, etiologic, and histologic features and likely represent components of a tumor spectrum. In dermatologic oncology, differentiating between AFX and PDS is pivotal as tumors with histological features consistent with PDS are more likely to behave in a clinically aggressive manner. Importantly, the term “pleomorphic dermal sarcoma” (PDS) is a more appropriate designation than “undifferentiated pleomorphic sarcoma” (UPS) for describing deeper, more aggressive, histologically high-grade cutaneous tumors that otherwise resemble AFX. Surgery remains the gold standard for treatment. In the setting of AFX, excision with the Mohs micrographic technique appears to offer superior tumor control rates while maintaining greater tissue preservation over wide local excision and should be considered first line. In the setting of PDS, optimal management is less clear given the paucity of available data. However, due to its greater propensity to recur and metastasize, extirpation with complete tumor margin control appears paramount. The roles of imaging and SLNB in management and clinical outcomes of AFX and PDS are unclear given the lack of available data. In reality, these tools are unlikely to be helpful in most cases of AFX. However, in the setting of PDS, emerging literature indicates that these tumors are inherently higher risk, and thus, imaging and SLNB may be helpful in select cases. Additionally, radiation therapy may be of adjuvant benefit for these tumors when clear surgical margins cannot be obtained. While traditional chemotherapy has been largely ineffectual, the recent discovery of key oncogenetic mutations has allowed for the identification of several potential molecular drug targets that may have a therapeutic role with future study. In the unfortunate setting of metastatic disease, a multidisciplinary approach is optimal. Further studies are needed to establish definitive conclusions regarding risk stratification and best management practices.
http://ift.tt/2f0MI7H
0 notes